SCHEMBL6609835

SCHEMBL6609835

C=C(C(=O)OC)N(Cc1ccccc1NC(=O)CNC(C)=O)S(=O)(=O)c1ccc(OC)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.48
GRK2 P25098 1/20 0.48
PPARG P37231 1/20 0.48
KMT2A Q03164 1/20 0.48
CTDSP1 Q9GZU7 1/20 0.48
NR2E3 Q9Y5X4 1/20 0.48
NCOR2 Q9Y618 1/20 0.48
KDM4E B2RXH2 3/20 0.47
ATM Q13315 1/20 0.43
HSD17B10 Q99714 1/20 0.43
KEAP1 Q14145 3/20 0.42
NFE2L2 Q16236 1/20 0.41
CA2 P00918 1/20 0.40
MMP1 P03956 1/20 0.40
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40
MMP8 P22894 1/20 0.40
MMP13 P45452 1/20 0.40
GAA P10253 1/20 0.40
CXCR3 P49682 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5656058 0.90 POLB (0.48) POLBGRK2PPARGKMT2ACTDSP1
SCHEMBL6610937 0.88 POLB (0.48) POLBGRK2PPARGKMT2ACTDSP1
SCHEMBL6608669 0.88 KMT2A (0.48) POLBGRK2PPARGKMT2ACTDSP1
SCHEMBL6614500 0.85 KMT2A (0.52) POLBGRK2PPARGKMT2ACTDSP1
SCHEMBL6610841 0.85 KEAP1 (0.48) POLBGRK2PPARGKMT2ACTDSP1
SCHEMBL6607925 0.84 POLB (0.50) POLBGRK2PPARGKMT2ACTDSP1
SCHEMBL5656436 0.84 LMNA (0.48) POLBGRK2PPARGKMT2ACTDSP1
SCHEMBL6611811 0.83 KDM4E (0.48) POLBGRK2PPARGKMT2ACTDSP1
SCHEMBL6608209 0.82 KEAP1 (0.47) POLBGRK2PPARGKMT2ACTDSP1
SCHEMBL6613405 0.82 KEAP1 (0.44) POLBGRK2PPARGKMT2ACTDSP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1147095-B1 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS WYETH CORP (US) 2004-08-11 EP disclosed
US-6544984-B1 Treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss. AMERICAN CYANAMID COMPANY 2003-04-08 US disclosed
EP-1147095-A1 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS American Cyanamid Company (US) 2001-10-24 EP disclosed
EP-1051407-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS American Cyanamid Company (US) 2000-11-15 EP disclosed
WO-2000044730-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]BENZODIAZEPINE-3-HYDROXAMIC ACID AS MATRIX METALLOPROTEINASE INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-08-03 WO disclosed
US-6071903-A ENZYME INHIBITORS OF MATRIX METALLOPROTEINASES (MMPS); ANTITUMOR,-CARCINOGENIC AND -ARTHRITIC AGENTS; OSTEOARTHRITIS; RHEUMATOID DISEASES; DEGENERATIVE CARTILAGE LOSS; LONG-ACTING, ORALLY BIOAVAILABLE NONPEPTIDE INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-06-06 US disclosed
WO-1999037625-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS AMERICAN CYANAMID COMPANY (US) 1999-07-29 WO disclosed